Inclusion Criteria:

- Signed informed consent.

- Participation in the previous clinical trial SP848-AK-1101.

- Patient with complete clinical clearance (i.e. no previously existing AK-lesion
present) at the end of the trial SP848-AK-1101 or Non-Responder who withdrew from the
trial prematurely.

Exclusion Criteria:

- Evidence of unstable or uncontrolled clinically significant medical conditions as
determined by the investigator (e.g., cardiovascular, immunological, hematologic,
hepatic, neurologic, renal, endocrine, collagen-vascular, infectious,
gastrointestinal abnormalities or diseases).

- Evidence of systemic cancer.

- Dermatological disease or condition in the former treatment or surrounding area that
might impair trial assessments (e.g., rosacea, atopic dermatitis, eczema) as assessed
by the investigator.